The estimated Net Worth of William Bonello is at least 3.94 百万$ dollars as of 28 April 2022. Mr. Bonello owns over 5,727 units of Neogenomics stock worth over 3,124,148$ and over the last 6 years he sold NEO stock worth over 0$. In addition, he makes 820,145$ as President、 Informatics and Director of Investor Relations at Neogenomics.
Sign up
Mr. Bonello NEO stock SEC Form 4 insiders trading
William has made over 9 trades of the Neogenomics stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 5,727 units of NEO stock worth 43,067$ on 28 April 2022.
The largest trade he's ever made was exercising 60,203 units of Neogenomics stock on 26 February 2019 worth over 473,196$. On average, William trades about 11,675 units every 77 days since 2019. As of 28 April 2022 he still owns at least 191,548 units of Neogenomics stock.
You can see the complete history of Mr. Bonello stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
William Bonello biography
William B. Bonello serves as President, Informatics and Director of Investor Relations of the Company. Mr. Bonello most recently served as our Chief Strategy and Corporate Development Officer helping to formulate the company's growth strategy. Bill will continue to serve as Director of Investor Relations, a position he has held since 2018. Prior to joining NeoGenomics, Bill worked as a healthcare equity analyst covering diagnostic services and product stocks at Craig-Hallum and at a variety of firms, and was also Senior Vice President for Investor Relations at LabCorp. Mr. Bonello received his B.A. degree from Carleton College and his MBA from the Kellogg School of Management at Northwestern University.
What is the salary of William Bonello?
As the President、 Informatics and Director of Investor Relations of Neogenomics, the total compensation of William Bonello at Neogenomics is 820,145$. There are 4 executives at Neogenomics getting paid more, with Douglas VanOort having the highest compensation of 3,648,730$.
How old is William Bonello?
William Bonello is 55, he's been the President、 Informatics and Director of Investor Relations of Neogenomics since 2020. There are 16 older and 10 younger executives at Neogenomics. The oldest executive at Neogenomics Inc. is Raymond Hipp, 77, who is the Independent Director.
What's William Bonello's mailing address?
William's mailing address filed with the SEC is 9490 NEOGENOMICS WAY, , FORT MYERS, FL, 33912.
Insiders trading at Neogenomics
Over the last 12 years, insiders at Neogenomics have traded over 310,374,253$ worth of Neogenomics stock and bought 167,456 units worth 1,699,153$ . The most active insiders traders include Electric Coge Medical Syste...、Oort Douglas M Van、Steven C Jones. On average, Neogenomics executives and independent directors trade stock every 23 days with the average trade being worth of 2,654,175$. The most recent stock trade was executed by Alicia C Olivo on 15 August 2024, trading 1,040 units of NEO stock currently worth 16,692$.
What does Neogenomics do?
neogenomics laboratories is a leading cancer diagnostic reference laboratory that has provided high-quality cancer testing and partnership programs to pathologists and oncologists for over 10 years. we work every day to achieve our common purpose of saving lives by improving patient care through communication, accuracy, reliability, and efficiency. our areas of expertise include cancer cytogenetics with industry-leading turnaround times; hematologic and solid tumor fish testing with the largest menu of technical-only services available; 10-color flow cytometry; ihc supported by an extensive antibody library; and over 100 molecular oncology tests comprising the most comprehensive combination of multiparameter profiles and targeted biomarker tests in the industry. our technical-only testing programs feature on-demand or live training and are available to pathologists who wish to sign out fish, flow cytometry, and/or ihc. neogenomics’ extremely fast test development cycle means we are hig
What does Neogenomics's logo look like?
Complete history of Mr. Bonello stock trades at Neogenomics
Neogenomics executives and stock owners
Neogenomics executives and other stock owners filed with the SEC include:
-
Douglas VanOort,
Chairman of the Board, Chief Executive Officer -
Robert Shovlin,
President - Clinical Services Division -
Lawrence Weiss,
Chief Medical Officer -
George Cardoza,
President - Pharma Services Division -
William Bonello,
President, Informatics and Director of Investor Relations -
Douglas M. Brown,
Chief Strategy & Corp. Devel. Officer -
Kathryn McKenzie,
Chief Financial Officer -
Steven Ross,
Chief Information Officer -
Steven Jones,
Director -
Alison Hannah,
Independent Director -
Lynn Tetrault,
Lead Independent Director -
Raymond Hipp,
Independent Director -
Bruce Crowther,
Independent Director -
Kevin Johnson,
Independent Director -
Stephen Kanovsky,
Independent Director -
Michael Kelly,
Independent Director -
Rachel Stahler,
Director -
Douglas Brown,
Chief Strategy and Corporate Development Officer -
Denise Pedulla,
General Counsel, Corporate Secretary -
Jennifer Balliet,
Vice President, Chief Culture Officer -
Stephanie Bywater,
Chief Compliance Officer -
Cynthia Dieter,
Chief Accounting Officer, Controller -
Dr. Steven G. Brodie FACMG, Ph.D.,
Sr. VP of Laboratory Operations -
George A. Cardoza,
Pres & COO of Lab Operations -
Marcus B. Silva J.D., M.B.A.,
Chief Marketing Officer -
Halley E. Gilbert Esq., J.D.,
Chief Legal Officer -
Charlie Eidson,
Director of Investor Relations and Corp. Devel. -
John Mooney,
Chief Technology Officer -
Cynthia J. Dieter,
Chief Accounting Officer & Controller -
Mark W. Mallon,
CEO & Director -
William J Robison,
Director -
Maher Albitar,
Chief Medical Officer -
Sharon Virag,
Chief Financial Officer -
David Sholehvar,
President, Clinical Services -
Neil Gunn,
Director -
Elizabeth Floegel,
Director -
Anthony P. Zook,
Director -
Christopher M Smith,
Chief Executive Officer -
Mark Alan Machulcz,
Vice President of Operations -
Michael T Dent,
Director -
Steven G. Brodie,
Chief Scientific Officer -
Steven Caspen Select Health...,
Executive VP of FinanceExecutive VP of Finance -
Robert H. Horel,
Vice President andGM PathLogic -
Robert P Gasparini,
Chief Science Officer -
Halley E Gilbert,
Chief Legal Officer -
Gina M Wallar,
President, Pharma Services -
Mark Mallon,
Chief Executive Officer -
Clive Morris,
President of Inivata -
Oort Douglas M Van,
Director -
David Daly,
Director -
Vishal Sikri,
President Advanced Diagnostics -
David Brian Perez,
Director -
Jeffrey Scott Sherman,
Chief Financial Officer -
Shashikant Kulkarni,
Chief Scientific Officer -
Alicia C Olivo,
General Counsel -
Melody Harris,
Chf Ops Off, Pres, Informatics -
Greg D Aunan,
Chief Accounting Officer -
Warren Stone,
Chief Commerical Officer